What is HC Wainwright's Estimate for RARE Q1 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for Ultragenyx Pharmaceutical in a research report issued on Wednesday, November 6th. HC Wainwright analyst E. Arce expects that the biopharmaceutical company will post earnings of ($1.20) per share for the quarter. HC Wainwright has a "Buy" rating and a $95.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($6.29) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical's Q4 2025 earnings at ($0.96) EPS.

RARE has been the topic of a number of other reports. The Goldman Sachs Group increased their target price on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. Wedbush lifted their target price on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the company a "neutral" rating in a report on Friday, August 2nd. Royal Bank of Canada restated an "outperform" rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday. Canaccord Genuity Group increased their price target on Ultragenyx Pharmaceutical from $109.00 to $121.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Barclays lowered their price objective on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an "overweight" rating for the company in a research report on Monday, August 5th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of "Moderate Buy" and an average price target of $86.69.

Ultragenyx Pharmaceutical Stock Down 0.2 %

NASDAQ RARE traded down $0.09 on Thursday, reaching $50.43. The stock had a trading volume of 706,135 shares, compared to its average volume of 781,253. The stock has a fifty day moving average price of $55.19 and a two-hundred day moving average price of $48.12. Ultragenyx Pharmaceutical has a 12-month low of $34.06 and a 12-month high of $60.37. The firm has a market capitalization of $4.65 billion, a price-to-earnings ratio of -6.91 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping analysts' consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The company had revenue of $139.49 million for the quarter, compared to the consensus estimate of $135.28 million. During the same period in the previous year, the firm earned ($2.23) earnings per share. Ultragenyx Pharmaceutical's quarterly revenue was up 42.3% compared to the same quarter last year.

Insider Activity

In other news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Howard Horn sold 7,465 shares of the firm's stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total transaction of $393,853.40. Following the completion of the transaction, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at $4,869,800.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the sale, the chief executive officer now owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,556 shares of company stock worth $1,515,967 in the last 90 days. 5.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. UMB Bank n.a. increased its stake in Ultragenyx Pharmaceutical by 58.1% in the second quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 352 shares during the last quarter. US Bancorp DE increased its position in Ultragenyx Pharmaceutical by 5.8% during the first quarter. US Bancorp DE now owns 7,143 shares of the biopharmaceutical company's stock worth $334,000 after purchasing an additional 390 shares during the last quarter. Arizona State Retirement System raised its stake in Ultragenyx Pharmaceutical by 2.1% during the second quarter. Arizona State Retirement System now owns 20,744 shares of the biopharmaceutical company's stock worth $853,000 after purchasing an additional 434 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 8.7% in the 1st quarter. ProShare Advisors LLC now owns 6,074 shares of the biopharmaceutical company's stock valued at $284,000 after purchasing an additional 486 shares during the last quarter. Finally, KBC Group NV boosted its holdings in shares of Ultragenyx Pharmaceutical by 24.5% in the 3rd quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company's stock valued at $143,000 after purchasing an additional 506 shares during the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.